State Street’s DataMeds AI MEDS Stock Holding History

State Street’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,492	Closed	-$12K	–	4361
2026 Q1	$12K	Hold	2,492	–	–	﹤0.01%	4243
2025 Q4	$49.8K	Buy	2,492 +546	+28%	+$16K	﹤0.01%	4147
2025 Q3	$86.3K	Buy	+1,946	New	+$103K	﹤0.01%	4078

Other funds holding MEDS

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

State Street's MEDS Position: Q2 2026 in Review

State Street sold out of DataMeds AI (MEDS) in Q2 2026, closing a stake of 2,492 shares — an estimated $12K sold.

State Street first reported a position in MEDS in Q3 2025 and held it in 3 quarters. The position peaked at $86.3K in Q3 2025. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

State Street reported no remaining DataMeds AI position as of Q2 2026 after selling out during the quarter.
State Street sold 2,492 DataMeds AI shares in Q2 2026, an estimated $12K.
State Street first reported a position in DataMeds AI in Q3 2025 and held it in 3 quarters.
State Street's DataMeds AI position peaked at $86.3K in Q3 2025.
9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.